LM22A-4_COA_22628_MedChemExpress

GENMED SCIENTIFICS INC. U.S.A GMS10016.8 v.A GENMED真菌/酵母细胞内氧化应激活性氧初级荧光测定试剂盒产品说明书（中文版）主要用途GENMED真菌/酵母细胞内氧化应激活性氧初级荧光测定试剂是一种旨在通过透膜荧光染色剂二氯荧光乙酰乙酸盐，在细胞氧化条件下，产生荧光，来定量检测细胞内活性氧族的生成和增加的权威而经典的技术方法。

该技术由大师级科学家精心研制、成功实验证明的。

其适用于各种实验用真菌/酵母菌株细胞内氧化应激活性氧的分析。

可以被用于细胞凋亡、信号传递、衰老和代谢等的研究。

产品严格无菌，即到即用，操作简易，活体检测，性能稳定，荧光清晰。

技术背景真菌/酵母细胞是一种低等单细胞真核生物，具有细胞生长快，易于培养，遗传操作简单明了等原核生物的特点。

作为模式生物，它具有比较完备的基因表达调控机制和表达产物的加工修饰能力，在分子遗传学方面认识最早，最先作为外源基因表达的细胞宿主。

超氧自由基阴离子（superoxide radical；O2-）、过氧化氢（hydrogen peroxide；H2O2）、羟自由基（hydroxyl radical）、单线态氧气（singlet oxygen）等细胞内活性氧族（Reactive Oxygen Species；ROS）的产生和增多，将导致细胞衰老或凋亡。

2',7'-二氯荧光乙酰乙酸盐（2',7'-dichlorofluorescein diacetate，DCFH-DA）一种完全自由通过细胞膜的染色剂。

一旦被过氧化氢氧化，便产生荧光。

据此测定细胞内活性氧族的浓度。

产品内容GENMED清理液（Reagent A）毫升GENMED染色液（Reagent B）微升GENMED稀释液（Reagent C）毫升产品说明书1份保存方式保存GENMED染色液（Reagent B）在－20℃冰箱里，严格避免光照；其余的保存在4℃冰箱里，有效保证6月用户自备1.5毫升离心管：用于真菌/酵母染色的容器载玻片：用于染色观察微型台式离心机：用于沉淀真菌/酵母细胞培养箱或恒温水槽：用于染色孵育比色皿：用于荧光定量分析（共聚焦）荧光显微镜：用于细胞荧光分析细胞流式仪：用于细胞荧光分析荧光分光光度仪：用于细胞荧光定量分析实验步骤实验开始前，将－20℃冰箱里的试剂盒中的GENMED染色液（Reagent B）置入冰槽里融化。

Inhibitors, Agonists, Screening LibrariesSafety Data Sheet Revision Date:May-24-2017Print Date:May-24-20171. PRODUCT AND COMPANY IDENTIFICATION1.1 Product identifierProduct name :BLU-554Catalog No. :HY-100492CAS No. :1707289-21-11.2 Relevant identified uses of the substance or mixture and uses advised againstIdentified uses :Laboratory chemicals, manufacture of substances.1.3 Details of the supplier of the safety data sheetCompany:MedChemExpress USATel:609-228-6898Fax:609-228-5909E-mail:sales@1.4 Emergency telephone numberEmergency Phone #:609-228-68982. HAZARDS IDENTIFICATION2.1 Classification of the substance or mixtureNot a hazardous substance or mixture.2.2 GHS Label elements, including precautionary statementsNot a hazardous substance or mixture.2.3 Other hazardsNone.3. COMPOSITION/INFORMATION ON INGREDIENTS3.1 SubstancesSynonyms:NoneFormula:C24H24Cl2N4O4Molecular Weight:503.38CAS No. :1707289-21-14. FIRST AID MEASURES4.1 Description of first aid measuresEye contactRemove any contact lenses, locate eye-wash station, and flush eyes immediately with large amounts of water. Separate eyelids with fingers to ensure adequate flushing. Promptly call a physician.Skin contactRinse skin thoroughly with large amounts of water. Remove contaminated clothing and shoes and call a physician.InhalationImmediately relocate self or casualty to fresh air. If breathing is difficult, give cardiopulmonary resuscitation (CPR). Avoid mouth-to-mouth resuscitation.IngestionWash out mouth with water; Do NOT induce vomiting; call a physician.4.2 Most important symptoms and effects, both acute and delayedThe most important known symptoms and effects are described in the labelling (see section 2.2).4.3 Indication of any immediate medical attention and special treatment neededTreat symptomatically.5. FIRE FIGHTING MEASURES5.1 Extinguishing mediaSuitable extinguishing mediaUse water spray, dry chemical, foam, and carbon dioxide fire extinguisher.5.2 Special hazards arising from the substance or mixtureDuring combustion, may emit irritant fumes.5.3 Advice for firefightersWear self-contained breathing apparatus and protective clothing.6. ACCIDENTAL RELEASE MEASURES6.1 Personal precautions, protective equipment and emergency proceduresUse full personal protective equipment. Avoid breathing vapors, mist, dust or gas. Ensure adequate ventilation. Evacuate personnel to safe areas.Refer to protective measures listed in sections 8.6.2 Environmental precautionsTry to prevent further leakage or spillage. Keep the product away from drains or water courses.6.3 Methods and materials for containment and cleaning upAbsorb solutions with finely-powdered liquid-binding material (diatomite, universal binders); Decontaminate surfaces and equipment by scrubbing with alcohol; Dispose of contaminated material according to Section 13.7. HANDLING AND STORAGE7.1 Precautions for safe handlingAvoid inhalation, contact with eyes and skin. Avoid dust and aerosol formation. Use only in areas with appropriate exhaust ventilation.7.2 Conditions for safe storage, including any incompatibilitiesKeep container tightly sealed in cool, well-ventilated area. Keep away from direct sunlight and sources of ignition.Recommended storage temperature:Powder-20°C 3 years4°C 2 yearsIn solvent-80°C 6 months-20°C 1 monthShipping at room temperature if less than 2 weeks.7.3 Specific end use(s)No data available.8. EXPOSURE CONTROLS/PERSONAL PROTECTION8.1 Control parametersComponents with workplace control parametersThis product contains no substances with occupational exposure limit values.8.2 Exposure controlsEngineering controlsEnsure adequate ventilation. Provide accessible safety shower and eye wash station.Personal protective equipmentEye protection Safety goggles with side-shields.Hand protection Protective gloves.Skin and body protection Impervious clothing.Respiratory protection Suitable respirator.Environmental exposure controls Keep the product away from drains, water courses or the soil. Cleanspillages in a safe way as soon as possible.9. PHYSICAL AND CHEMICAL PROPERTIES9.1 Information on basic physical and chemical propertiesAppearance White to light yellow (Solid)Odor No data availableOdor threshold No data availablepH No data availableMelting/freezing point No data availableBoiling point/range No data availableFlash point No data availableEvaporation rate No data availableFlammability (solid, gas)No data availableUpper/lower flammability or explosive limits No data availableVapor pressure No data availableVapor density No data availableRelative density No data availableWater Solubility No data availablePartition coefficient No data availableAuto-ignition temperature No data availableDecomposition temperature No data availableViscosity No data availableExplosive properties No data availableOxidizing properties No data available9.2 Other safety informationNo data available.10. STABILITY AND REACTIVITY10.1 ReactivityNo data available.10.2 Chemical stabilityStable under recommended storage conditions.10.3 Possibility of hazardous reactionsNo data available.10.4 Conditions to avoidNo data available.10.5 Incompatible materialsStrong acids/alkalis, strong oxidising/reducing agents.10.6 Hazardous decomposition productsUnder fire conditions, may decompose and emit toxic fumes.Other decomposition products - no data available.11.TOXICOLOGICAL INFORMATION11.1 Information on toxicological effectsAcute toxicityClassified based on available data. For more details, see section 2Skin corrosion/irritationClassified based on available data. For more details, see section 2Serious eye damage/irritationClassified based on available data. For more details, see section 2Respiratory or skin sensitizationClassified based on available data. For more details, see section 2Germ cell mutagenicityClassified based on available data. For more details, see section 2CarcinogenicityIARC: No component of this product present at a level equal to or greater than 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.ACGIH: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by ACGIH.NTP: No component of this product present at a level equal to or greater than 0.1% is identified as a anticipated or confirmed carcinogen by NTP.OSHA: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by OSHA.Reproductive toxicityClassified based on available data. For more details, see section 2Specific target organ toxicity - single exposureClassified based on available data. For more details, see section 2Specific target organ toxicity - repeated exposureClassified based on available data. For more details, see section 2Aspiration hazardClassified based on available data. For more details, see section 212. ECOLOGICAL INFORMATION12.1 ToxicityNo data available.12.2 Persistence and degradabilityNo data available.12.3 Bioaccumlative potentialNo data available.12.4 Mobility in soilNo data available.12.5 Results of PBT and vPvB assessmentPBT/vPvB assessment unavailable as chemical safety assessment not required or not conducted.12.6 Other adverse effectsNo data available.13. DISPOSAL CONSIDERATIONS13.1 Waste treatment methodsProductDispose substance in accordance with prevailing country, federal, state and local regulations.Contaminated packagingConduct recycling or disposal in accordance with prevailing country, federal, state and local regulations.14. TRANSPORT INFORMATIONDOT (US)This substance is considered to be non-hazardous for transport.IMDGThis substance is considered to be non-hazardous for transport.IATAThis substance is considered to be non-hazardous for transport.15. REGULATORY INFORMATIONSARA 302 Components:No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302.SARA 313 Components:This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.SARA 311/312 Hazards:No SARA Hazards.Massachusetts Right To Know Components:No components are subject to the Massachusetts Right to Know Act.Pennsylvania Right To Know Components:No components are subject to the Pennsylvania Right to Know Act.New Jersey Right To Know Components:No components are subject to the New Jersey Right to Know Act.California Prop. 65 Components:This product does not contain any chemicals known to State of California to cause cancer, birth defects, or anyother reproductive harm.16. OTHER INFORMATIONCopyright 2017 MedChemExpress. The above information is correct to the best of our present knowledge but does not purport to be all inclusive and should be used only as a guide. The product is for research use only and for experienced personnel. It must only be handled by suitably qualified experienced scientists in appropriately equipped and authorized facilities. The burden of safe use of this material rests entirely with the user. MedChemExpress disclaims all liability for any damage resulting from handling or from contact with this product.Caution: Product has not been fully validated for medical applications. For research use only.Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA。

Inhibitors, Agonists, Screening Libraries Data SheetBIOLOGICAL ACTIVITY:ML324 is a potent JMJD2 demethylase inhibitor with demonstrated antiviral activity.IC50 value: 920 nM(JMJD2E) [1]Target: JMJD2 demethylase inhibitorML324 is a probe molecule that displays submicromolar inhibitory activity toward JMJD2E (in vitro) and possesses excellent in vitro ADME properties. In contrast to previously reported inhibitors of the JMJD proteins, ML324 displays excellent cell permeabilityproviding an opportunity for more extensive cell–based studies of JMJD2 enzymes to be undertaken. In addition, ML324 demonstrates potent anti–viral activity against both herpes simplex virus (HSV) and human cytomegalovirus (hCMV) infection via inhibition viral IE gene expression. ML324 suppresses the formation of HSV plaques, even at high MOI, and blocks HSV–1 reactivation in a mouse ganglia explant model of latently infected mice.PROTOCOL (Extracted from published papers and Only for reference)JMJD2E qHTS FDH Assay [1]:Enzyme and buffer solutions (3 μL) were dispensed into a 1,536–well Greiner black solid–bottom assay plate. The library compounds (23 nL) were transferred using a Kalypsys pintool equipped with 1,536–pin array. The plate was incubated at room temperature (15min), and then a 1 μL aliquot of substrate solution was added to initiate the reaction. The plate was transferred to ViewLux imager where an initial reading using standard UV optics (Ex 340 nm, Em 450 nm) was obtained. The plate was then removed from the reader,incubated for 30 minutes at room temperature, and returned to the reader for a second fluorescence reading. A fully automated robotic screening system (Kalypsys Inc, San Diego, CA) was used to perform the above steps as described previously. Compound plates containing DMSO as a vehicle–only control were included at regular interval throughout the screen to monitor any systematic trend in the assay signal associated with reagent dispenser variation or decreases in enzyme specific activity. For activity calculations,percent values were computed as the difference in fluorescence intensity between last and first time points. The percentage activity was calculated from the median values of the catalyzed, or neutral control, and the uncatalyzed, or 100% inhibited, control,respectively, using in–house software.Inhibition of viral infection in cell culture [1]:Cells were treated with DMSO, LSD1 inhibitor (TCP, tranylcypromine, Sigma P8511), or JMJD2 inhibitorsand infected with HSV–1 or hCMV as described below. cDNA was produced from total RNA and quantitated using an ABI 7900HT (ABI SDS 2.3 Software). Viral yields were determined by titration.References:Product Name:ML324Cat. No.:HY-12725CAS No.:1222800-79-4Molecular Formula:C 21H 23N 3O 2Molecular Weight:349.43Target:Histone Demethylase Pathway:Epigenetics Solubility:DMSO: ≥ 33 mg/mL[1]. Rai G, et al. Discovery of ML324, a JMJD2 demethylase inhibitor with demonstrated antiviral activity.Caution: Product has not been fully validated for medical applications. For research use only.Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA。

原发性醛固酮增多症诊断中CXCR4受体显像的临床应用专家共识（2022）原发性醛固酮增多症（下文简称“原醛症”）是指肾上腺皮质自主分泌过量醛固酮，以致肾素-血管紧张素系统活性被抑制，患者出现以高血压伴或不伴低血钾为主要特征的临床综合征[1]。

醛固酮瘤（APA）和特发性醛固酮增多症（IHA）是原醛症最主要的亚型，分别约占原醛症的35%和60%。

其他少见类型包括原发性肾上腺皮质增生、家族性醛固酮增多症、分泌醛固酮的肾上腺皮质癌及异位醛固酮分泌瘤或癌[2]。

原醛症的分型诊断，尤其APA与IHA的鉴别，一直是原醛症诊疗过程中的重点和难点。

现阶段对于原醛症的分型诊断主要依据肾上腺影像学及肾上腺静脉插管采血（AVS）判断病灶位置及功能性。

CT 是首选的肾上腺影像学检查手段，有助于明确单侧/双侧肾上腺病变及病灶位置。

国际指南指出，合并自发性低钾血症、醛固酮明显高分泌且CT检查结果符合单侧肾上腺皮质腺瘤的年轻患者（年龄＜35岁），可直接手术而无需行AVS检测[1]。

国内研究显示，对于伴低钾血症的患者，如CT提示单侧孤立性低密度腺瘤（CT值＜20 Hu），诊断APA的特异度达95%[3]。

但CT易漏诊长径＜1 cm的小腺瘤或结节，且该检查不能提供功能信息，无法鉴别分泌醛固酮的功能性病灶和肾上腺无功能瘤。

总体而言，CT对于原醛症分型诊断的准确度为60%～70%。

AVS被认为是原醛症分型的“金标准”，可明确是否存在单侧优势分泌，其识别优势分泌侧的灵敏度为95%，特异度为100%[4]。

但AVS属于有创检查，且价格昂贵、需要住院检查、操作难度较大、插管有失败和术后并发症风险，故很难在各级医院大规模开展。

此外，目前国内外尚缺乏统一的AVS评估标准，不同研究中心在AVS操作方式、结果判读方面存在差异；且虽然AVS 可区分单侧和双侧病变，但单侧醛固酮优势分泌并非APA的特异性表现，如单侧肾上腺增生、不对称分泌的双侧肾上腺增生，在AVS检测中均可呈现为单侧优势分泌。